Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2017-02-20
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
NCT01185119
Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity
NCT01847456
Effects of Age and Obesity on Brain Insulin Sensitivity
NCT04372849
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
NCT01363609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Intranasal placebo administration
Placebo
placebo intranasal administration
Intranasal insulin
Intranasal insulin administration
intranasal insulin
intranasal administration of insulin (160 IU)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intranasal insulin
intranasal administration of insulin (160 IU)
Placebo
placebo intranasal administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intake of any medication
* HbA1C \<6%
* BMI 20-25 kg/m²
* Clinical routine blood parameters within the normal ranges
* All participants must agree to get informed of unexpected detected, clinical relevant findings.
Exclusion Criteria
* Any relevant cardiovascular disease
* Any surgery within the last three months
* Any neurologic or psychiatric disease
* Known allergies
* Hb \< 13 g/dl
* Presence of any contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.
* Claustrophobia
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tuebingen, Department of Internal Medicine IV
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GK-PET/MR Tü-014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.